Point72 Asset Management’s Kyverna Therapeutics KYTX Stock Holding History

Point72 Asset Management’s Portfolio KYTX Stock Details KYTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.92M	Buy	222,929 +190,745	+593%	+$1.59M	﹤0.01%	2327
2025 Q4	$303K	Buy	32,184 +5,008	+18%	+$37.2K	﹤0.01%	3468
2025 Q3	$163K	Sell	27,176 -28,346	-51%	-$113K	﹤0.01%	2159
2025 Q2	$170K	Buy	+55,522	New	+$137K	﹤0.01%	2010
2024 Q4	–	Sell	-34,482	Closed	-$169K	–	2524
2024 Q3	$169K	Buy	+34,482	New	+$266K	﹤0.01%	1820
2024 Q2	–	Sell	-20,900	Closed	-$519K	–	2546
2024 Q1	$519K	Buy	+20,900	New	+$583K	﹤0.01%	1638

Other funds holding KYTX

GGI

GordonMD Global Investments Beverely Hills, California $144M AUM

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

IHG

Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Point72 Asset Management's KYTX Position: Q1 2026 in Review

Point72 Asset Management increased its Kyverna Therapeutics (KYTX) stake by 593% in Q1 2026, buying an estimated $1.59M and bringing the position to 222,929 shares worth $1.92M. The position accounts for ﹤0.01% of the portfolio, ranked #2327.

Point72 Asset Management first reported a position in KYTX in Q1 2024 and has held it in 6 quarters since. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

Point72 Asset Management held 222,929 shares of Kyverna Therapeutics worth $1.92M as of Q1 2026.
Point72 Asset Management bought 190,745 Kyverna Therapeutics shares in Q1 2026, an estimated $1.59M.
Kyverna Therapeutics made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #2327 holding.
Point72 Asset Management first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 6 quarters since.
111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.